Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Observational × Neurofibromatosis 1 × Clear all

Status

Completed 20 Unknown 9 Recruiting 9 Active not recruiting 4 Terminated 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 9 Observational 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 122 Neoplasms 119 Lung Neoplasms 59 Prostatic Neoplasms 56 Carcinoma, Non-Small-Cell Lung 51 Colorectal Neoplasms 35 Multiple Myeloma 32 Melanoma 28 Pancreatic Neoplasms 27 Head and Neck Neoplasms 26 Brain Neoplasms 25 Neoplasm Metastasis 24 Ovarian Neoplasms 22 Carcinoma, Hepatocellular 22 Liver Neoplasms 21 Leukemia, Myeloid, Acute 19 Esophageal Neoplasms 18 Colonic Neoplasms 18 Lymphoma 17 Leukemia, Lymphocytic, Chronic, B-Cell 17 Sarcoma 16 Urinary Bladder Neoplasms 15 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Lymphoma, Non-Hodgkin 15 Glioma 15 Glioblastoma 15 Carcinoma, Renal Cell 15 Stomach Neoplasms 14 Lymphoma, Follicular 14 Uterine Cervical Neoplasms 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05683678 2025-04-04

US Selumetinib Registry

Alexion Pharmaceuticals, Inc.

Neurofibromatosis 1, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡